Abstract Library

#3386 Peptide Radio Receptor Therapy induces immune activation in patients with neuroendocrine tumors and might sensitize to immunotherapy

Introduction: Peptide Radio Receptor Therapy (PRRT) is a standard treatment in patients with neuroendocrine tumors (NET), but treatment responses are limited and novel therapy combinations are needed. Since radiation induced cell death is considered immunogenic, patients might benefit from a combination of PRRT with immunotherapies, such as immune checkpoint inhibitors (ICI).

Conference:

Presenting Author: Büttner S

Authors: Büttner S, Detjen K, Galler M, Siefert J, Wiedenmann B,

Keywords: NET, PRRT, checkpoint inhibitors, immune response, PD1, flow cytometry,

#1864 Analysis of mTOR, CXCR4 and PD-1 Checkpoint Pathways in Merkel Cell Neuroendocrine Carcinomas: Correlations with Prognosis and Viral Status

Introduction: Merkel cell carcinoma (MCC) is a rare and aggressive cutaneous neuroendocrine tumor. Prognostic factors currently included in the reference AJCC classification are mainly clinical.

Conference: 14th Annual ENETSConcerence (2017)

Presenting Author:

Authors: Benhamou J, Deschamps L, Vergier B, Pham-Ledard A, Carlotti A,

Keywords: Merkel cell carcinoma, mTor, CXCR4, PD-L1,

#1680 PD-1, PD-L1 and PD-L2 Expression in Well-Differentiated Small Bowel Gastrointestinal Neuroendocrine Tumours (Wd SB-NETs).

Introduction: Treatment options for patients with advanced Wd SB-NETs are limited.

Conference: 14th Annual ENETSConcerence (2017)

Presenting Author: Lamarca A

Authors: Lamarca A, Nonaka D, Breitwieser W, Ashton G, Barriuso J,

Keywords: immunotherapy,

#1630 The Positive Expression of PD-L1/PD-1 in Gastroenteropancreatic Neuroendocrine Neoplasias Correlates with Prognosis

Introduction: The incidence of Neuroendocrine Neoplasias (NENs) is increasing and their pathological characteristics, varied between races. However, the epidemiology of GEP-NENs in Chinese patients remains poorly characterized especially for the expression of important immune checkpoint protein PD1 and PD-L1.

Conference: 14th Annual ENETSConcerence (2017)

Presenting Author:

Authors: Yinying W, Chuying W,

Keywords: gastroenteropancreatic neuroendocrine neoplasias, PD-L1, PD-1, immunohistochemistry, prognosis,

#1561 PD1 and PDL1 Expression in Midgut Neuroendocrine Tumors

Introduction: PD1/PDL1 inhibitors have shown promising results in different carcinomas, and correlation between PDL1 expression and response to immunotherapy has been reported. No studies thus far have investigated the expression of PD1 or PDL1 in midgut NETs.

Conference: 13th Annual ENETSConcerence (2016)

Presenting Author:

Authors: Cives M, Strosberg J, Coppola D,

Keywords: midgut NETs, PD1, PD-L1, lymph node-like structures,